Introduction
Adoptive T cell therapy elicits long-lasting clinical responses in patients with malignant metastatic melanoma [1] . However, randomized clinical trials have failed to find similar results in other malignancies [2] . In addition, the adoptive infusion of autologous natural killer (NK) cells has yet to show clinical benefit in treating cancer patients [3] . This clinical failure may be in part due to sustained immunological selection pressure on tumor cells resulting in the development of tumor escape variants that are effectively invisible to the immune system. One of the most frequent immune escape strategies tumors use to avoid being detected by cytotoxic T cells is down-regulation of MHC class I [4, 5] . As a result, individual cells may display differential expression of MHC class I within a growing tumor mass [6] . While MHC class I-positive tumor cells are targeted by tumor-specific T cells, MHC class I-negative tumor cells can be killed by NK cells due to lack of ligation of inhibitory killer immunoglobulin-like receptors (KIRs) on NK cells. Simultaneous adoptive cell therapy with tumor-specific T cells and NK cells may therefore offer a strategy to generate broader anti-tumor responses compared with infusion of NK or T cells as a monotherapy. Such combined therapy could potentially result in improved clinical responses.
Besides secreting lytic granules, T and NK cells ligate death receptors on tumor cells to induce apoptosis [7] [8] [9] [10] .
We and others have recently demonstrated that exposure to the proteasome inhibitor bortezomib significantly up-regulated the expression of death receptors to TNF-related apoptosis-inducing ligand (TRAIL) [11] [12] [13] . However, bortezomib-treated tumors sensitized to NK cell apoptosis simultaneously acquire resistance to antigen-specific T cells [14] . As bortezomib predominantly inhibits the chymotryptic-like activity of the 20S proteasome [15] , impaired antigen processing and presentation prevent tumor-specific T cells from killing bortezomib-treated tumors.
We have recently identified the small molecule b-AP15 as a novel inhibitor of proteasome deubiquitinating activity [16] . Cells treated with b-AP15 accumulate polyubiquitinated proteins, with similar kinetics to cells treated with bortezomib. b-AP15-induced proteasome inhibition was concomitant with the up-regulation of apoptotic markers and the accumulation of cell cycle regulatory proteins, leading to cell cycle arrest and apoptosis independent of the tumor suppressor p53 or overexpression of the BCL2 oncogene, which are implicated in bortezomib resistance.
In the present study, we sought to investigate whether inhibition of proteasome deubiquitinating activity sensitizes tumors to both T and NK cell-mediated killing. Similarly to bortezomib, we found that treatment with subapoptotic doses of b-AP15 resulted in an increased surface expression of TRAIL-R2 and decreased expression of cFLIP in tumor cells. As a consequence, b-AP15-treated tumors displayed an increased sensitivity to killing by both NK and T cells in vitro. Furthermore, significantly increased survival times were observed in mice treated with b-AP15 followed by combined infusion of syngeneic NK and tumor-specific T cells relative to mice treated with b-AP15 followed by infusion of either syngeneic NK or tumor-specific T cells.
Materials and methods

Human NK and T cell culture
Human NK cells were isolated from peripheral blood mononuclear cells (PBMC) of healthy donors and melanoma patients (ethical permit dnr #2009/848-3) by negative immuno-magnetic bead depletion (Miltenyi Biotech, BergischGladbach, Germany). Purified NK cells (C95 %) were expanded with 25 Gy irradiated autologous PBMC (feeder cells) at a 1:20 cell ratio (NK: feeder) in X-VIVO 20 media (Lonza, Verviers, Belgium) supplemented with 10 % heat-inactivated human AB serum (Karolinska Hospital, Stockholm, Sweden) and 500 U/ml recombinant human interleukin-2 (IL-2) (Novartis pharma GmbH, Nurnberg, Germany). Fresh medium containing 500 U/ml IL-2 was added on days 5, 8 and 11 , and NK cells were tested for cytotoxicity or infused into mice on days 11-14 of expansion. Contamination of CD3-positive T cells was \1 %.
Tumor-specific T cells were isolated from tumor biopsies from HLA-A2-positive melanoma patients. Biopsies were manually dissected into small pieces and transferred to 24-well plates followed by incubation with 6,000 U/ml of IL-2 in X-vivo 20 medium supplemented with 5 % AB serum for 6 days. Tumor infiltrating lymphocytes were screened for antigen-specificity by intracellular staining for interferon-gamma (IFNc) and IL-2 (Biolegend, San Diego, USA) against T2 cells pulsed with HLA-A2-binding melanoma-associated peptides gp100, MAGE-1, MAGE-3, Survivin and Mart-1 (Genecust, Dudelang, Luxembourg); 8.4 % of T cells stained positive for IFNc and IL-2 after co-culture with Mart1 (ELAGIGILTV) -pulsed T2 cells, but not against any of the other peptides. These TILs were expanded in X-vivo 20 medium supplemented with 5 % AB, 500 U/ml IL-2 and 50 ng/ml anti-CD3 antibody (Janssen-Cilag, Sollentuna, Sweden) and irradiated (40 Gy) allogeneic PBMC. Medium supplemented with 500 U/ml of IL-2 was replenished on days 5 and 8 of culture. Purity of CD3-positive T cells was C94 % with \1 % contamination of CD56-positive NK cells. Expanded NK and T cells were tested against K562 cells (Supplementary Fig. 1A ). T cells were tested negative against the HLA-A2-negative tumor cell line EST115 (Table 1) .
Murine NK and T cell culture Murine NK cells were isolated from BALB/c splenocytes by negative bead depletion (MACS, Miltenyi Biotech) and cultured in 96 U-bottom plates in RPMI1640 medium supplemented with 10 % FCS, 50 lM Beta-mercapethanol, 25 lg/ml gentamycin, 2 mM L-glutamine, 1 % NEAA (Invitrogen, Eugene, Oregon, USA) and 500 U/ml of human IL-2 for 5 days. Murine tumor-specific T cells were generated by whole tumor cell vaccination. Briefly, BALB/ c mice received three weekly intraperitoneal (i.p) injections of 1 9 10 6 irradiated (10,000 Rad) D2F2 breast cancer cells. Spleen and lymphnodes were collected and re-stimulated with irradiated (5,000 Rad) D2F2 and recombinant human IL-2 (100 U/ml) in vitro for 4 days. T cells were tested for tumor reactivity in a 51Cr-release assay against D2F2 cells, YAC-1 cells and RENCA cells. Generated T cells tested negative against RENCA (Table 1) and YAC-1 tumors ( Supplementary Fig. 1B All cell lines were maintained in RPMI1640 media with 10 % fetal calf serum (Invitrogen, Eugene, Oregon, USA), 50 U/ml penicillin and 50 mg/ml streptomycin (Invitrogen).
Reagents and antibodies
Tumor cells were treated in vitro with 1 lM of b-AP15 (3,5-bis[(4-nitrophenyl)methylidene]-1-prop-2-enoylpiperidin-4-one, Oncotargeting AB Uppsala, Sweden) for 3 h before analysis for phenotype by flow cytometry or susceptibility to killing in cytotoxicity assays. J82 and EST027 cells were treated with 20 nM of bortezomib (Millennium Pharmaceuticals, Inc.) for 20 h before testing in cytotoxicity assays. To evaluate TRAIL-or Fas ligand-mediated cytotoxicity of human tumors, recombinant TRAIL or Fas ligand (Peprotech, London, UK) was added to cells in cytotoxicity assays at 100 and 150 ng/ml, respectively. Concanamycin A (CMA; Sigma, Schnelldorf, Germany) was added in cytotoxicity assays at 100 nM to degrade perforin. Isolated and expanded NK cells and TILs were assessed for purity and TRAIL expression by flow cytometry after staining with antibodies against human CD3, CD56, CD4 and CD8, TRAIL (Biolegend). Human tumors were stained for TRAIL-R1, R2, R3, Fas, MICA/B and Nectin-2, MHC class I (Biolegend). Murine BALB/c D2F2 tumor cells were stained with TRAIL-R2 (Biolegend) before and after treatment with 1 lM b-AP15 for 3 h. Apoptosis was analyzed by staining with annexin V and 7-AAD (Biolegend). All flow cytometry experiments were acquired on an LSRII (BD Biosciences, San Jose, California, USA), and data were analyzed using FlowJo software (Tree Star, Ashland, USA). Cytotoxicity and cytokine production assays
In chromium51-release cytotoxicity assays, target cells were labeled with 51Cr (50 lCi) (PerkinElmer, Groningen, The Netherlands) and seeded in 96 U-bottom plates in triplicates. Human or murine NK or T cells were added to target cells at different E/T ratios. Following 18-h incubation, 25 ll of supernatant was transferred onto Luma plates (PerkinElmer) and analyzed using MicroBeta scintillation (TRILUX 1450) counter (PerkinElmer). For intracellular staining of IFNc, 10,000 tumor cells were plated with 20,000-200,000 NK or T cells in a 96 U-bottom plate and incubated for 6 h. Staining was performed following the manufacturer's instructions (BD Biosciences). Where indicated, cytotoxicity assays were performed in presence of neutralizing antibodies against TRAIL (10 lg/ml), NKG2D (10 lg/ml), Fas ligand (10 lg/ml), DNAM-1(10 lg/ml) (Biolegend) or CMA (100 nM).
In vivo tumor models
All animal experiments were performed at the Department of Microbiology, Tumor and Cell Biology (MTC) or the Swedish Institute for Infectious Disease Control, Karolinska Institutet under approved study N42/10. SCID/Beige mice were purchased from Charles River (Sulzfeld, Germany). SCID/Beige mice (8-12 weeks old) were injected subcutaneously (s.c) with J82 tumors (3 9 10 6 /mouse) in the right flank. When tumors were palpable ([1 mm 3 , day 10), mice were grouped to receive either vehicle (n = 4) or b-AP15 (n = 4) at 2.5 mg per kg of body weight (i.p). The following day, mice were injected intravenously (i.v) with 2 9 10 6 NK cells or 4 9 10 6 TILs. In cytotoxicity assays, in vitro killing of untreated J82 tumors was approximately twofold higher by NK cells compared with TILs; therefore, a 1:2 ratio of infused NK cells and TILs was used. Mice were treated for a total of three cycles, receiving injections of b-AP15 on days 12, 19 and 26 and cell infusions on days 13, 20 and 27 post-tumor injection.
To investigate the potential synergistic effect of combined NK and T cell therapy, immune competent male BALB/c mice were injected s.c with D2F2 cells (100,000/mouse) in the right flank. Alternatively, BALB/c mice were injected i.v with lentiviral-transduced luciferase (AMS Biotechnology, UK) D2F2 cells (100,000/mouse). Within one week, when s.c tumors were palpable ([5 mm 3 , day 6) or pulmonary metastases were visible by bioluminescence imaging (day 3), BALB/c mice were treated with either vehicle (PBS) or three weekly cycles of b-AP15 (2.5 mg/kg) followed by the next day infusion of NK cells (0.75-1.5 9 10 6 cells) and/or tumor-specific T cells (1-2 9 10 6 cells). Mice treated with the combination of both NK and T cells received the same number of total cells compared to mice receiving NK or T cells alone. Tumor progression was assessed by palpation twice weekly or by in vivo bioluminescence imaging. In vivo imaging was performed by injecting mice with luciferin (3 lg/mouse, i.p). Mice were imaged the IVIS camera platform (Caliper LifeSciences Benelux & Nordic, Belgium). The in vivo experiments were repeated twice with 4-6 mice per treatment group.
Statistical analysis
All statistical analyses were performed using GraphPad Prism 5.0 software. The in vitro data were analyzed by paired or unpaired t test, and in vivo data were analyzed using unpaired t test, two-way ANOVA and logrank (Mantel-Cox) test. Correlation tests were performed using Pearson's correlation test. p-values below 0.05 were considered statistically significant between treatment groups. (Fig. 1a) . In contrast, no significant change in expression of Fas was observed in these cell lines following treatment with b-AP15 (Fig. 1b) . Additionally, no changes were observed in the expression of TRAIL-R1, TRAIL-R3, MHC class I, MICA/B and Nectin-2 following treatment of J82 cells with b-AP15 (Supplementary Fig. 1C) . In contrast, expression of cFLIP was down-regulated in J82 cells following exposure to b-AP15 ( Supplementary Fig. 1D ). When tumor cell lines were examined for susceptibility to TRAIL-induced apoptosis, b-AP15 pre-treatment resulted in significantly increased TRAIL-mediated killing in several tumor cell lines including HCT116, A498, J82, RT4, MDA453 and DU145 (p = 0.002) (Fig. 1c) . Killing by recombinant FasL was higher in b-AP15-treated A498 cells compared with untreated cells. However, no increase in FasL-mediated killing was observed in any of the other cells lines after treatment with b-AP15 (p = 0.07) (Fig. 1d) .
Results
Increased
b-AP15 sensitizes tumor cells to TRAIL-mediated NK and T cell killing in vitro Upon activation with IL-2, human NK and T cells express TRAIL (Supplementary Fig. 2A ). We next investigated whether b-AP15-treated tumor cells would be more sensitive to killing by activated NK and T cells. Indeed, human tumor cells treated with b-AP15 were significantly more sensitive to killing by NK (p \ 0.0002) and tumor (Mart1)-specific T cells (p = 0.02) ( Fig. 2a ; Table 1 ). In contrast to our previous findings, where tumor cell lines pre-treated with the proteasome inhibitor bortezomib were resistant to T cell-mediated killing [14] , b-AP15 pre-treated J82 and EST027 cells were highly sensitized to T cell-mediated killing relative to untreated or bortezomib-treated cells (Supplementary Fig. 2B ). Importantly, b-AP15 did not sensitize fibroblasts to NK cell-mediated killing (Table 1) .
To confirm if the underlying mechanism of killing was dependent on TRAIL-R2 signaling, cytotoxicity assays were performed in the presence of neutralizing antibodies. Both NK and T cell-mediated killing of b-AP15-treated human tumors was significantly reduced in the presence of neutralizing antibodies to TRAIL. Although overall cytotoxicity was reduced in presence of the perforin inhibitor concanamycin A and neutralizing antibodies to Fas ligand, b-AP15 still sensitized tumors to NK and T cell-mediated killing in presence of these inhibitors (Fig. 2b) . Furthermore, no significant reduction in killing was observed in presence of neutralizing antibodies to NKG2D or DNAM-1 Given that treatment with b-AP15 results in increased TRAIL-R2 expression and decreased cFLIP expression, we next addressed which of these events are required for b-AP15-mediated sensitization to NK cell killing. An overall positive correlation in NK cell-mediated killing and expression of TRAIL-R2 was observed in tumor cell lines before and after treatment with b-AP15 (p = 0.006). Although an average decrease of 56 ± 11 % in the expression of cFLIP was observed following treatment with b-AP15 in several cell lines (J82, JOHW, JuSo, and HeLa), no significant overall correlation was found between the cFLIP expression and sensitivity to NK cellmediated killing (Fig. 3a) . Furthermore, increased NK cell-mediated killing was only observed in individual cell lines where expression of TRAIL-R2 was significantly increased. In contrast, NK cell-mediated killing was independent of decreased cFLIP expression after b-AP15 treatment (Fig. 3b) (Fig. 4a-c) .
We next asked whether combined infusion of both NK and T cells would result in further delayed tumor progression in b-AP15-treated mice. In vitro, treatment with b-AP15 resulted in a minor up-regulation of TRAIL-R2 expression. Nevertheless, this increase in expression was sufficient to sensitize D2F2 tumor cells to NK and T cellmediated killing. Furthermore, the level of murine NK cell and T cell killing of b-AP15-treated tumor cells was reduced in the presence of neutralizing antibodies to TRAIL ( Supplementary Fig. 3A , B and C). In addition, RENCA, but not B16, melanoma tumor cell lines were efficiently killed by NK cells following exposure to b-AP15 compared with untreated tumor cells (Table 1) . Moreover, murine NK and tumor-specific T cells displayed elevated IFNc production when co-cultured with b-AP15-treated D2F2 cells compared with those co-cultured with untreated D2F2 tumors (data not shown).
In mice-bearing s.c implanted syngeneic D2F2 tumors, treatment with b-AP15, NK cells or T cells alone did not result in reduced tumor burden compared with untreated tumor-bearing BALB/c mice. After three infusions, the median tumor sizes were 334 ± 11 (untreated mice), 326 ± 91 (b-AP15-treated mice), 340 ± 84 (NK celltreated mice), 260 ± 23 (T cell-treated mice) and 363 ± 25 (NK cell ? T cell-treated mice). However, compared with mice treated with b-AP15 alone or NK ? T cell-treated mice without b-AP-15, treatment with b-AP15 followed by infusion of both NK and T cells resulted in significantly reduced tumor burden in mice-bearing s.c tumors (p B 0.01; Fig. 5a ).
In addition, bioluminescence imaging of mice implanted with luciferase expressing D2F2 cells, showed a significant decrease in tumor burden in mice pre-treated with b-AP15 and co-infused with NK and T cells (p B 0.002, Fig. 5b, c) . (Fig. 5d) .
Discussion
Here we demonstrate that inhibition of proteasome deubiquitinating activity leads to sensitization of tumor cells to NK and T cell-mediated killing and that the mechanism of sensitization centers upon up-regulation of TRAIL-R2. Several chemotherapeutical agents have been shown to increase TRAIL receptor expression on tumor cells [17, 18] . We and others previously demonstrated that treatment with the proteasome inhibitor bortezomib increases TRAIL-R2 expression on tumor cells resulting in an increased killing by activated NK cells via TRAIL in vitro [12, 19] . Whether bortezomib can sensitize tumor cells to T cell-mediated killing is less clear. Bortezomib was recently shown to inhibit NF-jB activity and restores MART-1 expression and pro-apoptotic signaling, resulting in sensitization of melanoma tumors to killing by TCR-engineered CTLs [20] . We have demonstrated that bortezomib-treated tumor cells are resistant to killing by tumor-specific TILs due to impaired antigen processing and presentation [14] . Differences in T cell preparation and source may account for these differences. In accordance with our previous findings, we show that treatment with bortezomib results in increased NK but abrogated T cell-mediated killing of tumor cells. However, the same tumor cells were rendered sensitive to killing by both NK and T cells following exposure to the proteasome deubiquitinatinase inhibitor b-AP15. b-AP15 inhibits the deubiquitinating activity of the regulatory 19S particle of the proteasome resulting in impaired degradation of cellular proteasome substrates [16] . However, unlike bortezomib, the proteolytic activities of the 20S core proteasome are not inhibited and thus immunoproteasome processing and presentation of antigenic peptides to T cells are not expected to be impaired [16] . Therefore, we hypothesized that b-AP15 may enhance NK cell killing in a manner similar to bortezomib, but without dampening antigen processing and T cell-mediated killing.
Overall, b-AP15 induced up-regulation of TRAIL-R2 and down-regulation of cFLIP in human tumor cell lines in vitro. We found that up-regulation of TRAIL-R2, rather than down-regulation of cFLIP, was associated with b-AP15-induced sensitization to NK cell-mediated killing. We previously demonstrated that the amplitude of NK cellmediated lysis positively correlated with the degree of induction of TRAIL-R2 expression following treatment with bortezomib [19] . Several studies have demonstrated that down-regulation of cFLIP in tumor cells is required for sensitization to TRAIL-mediated killing [21, 22] . In contrast, Ganten et al. [23] showed that proteasome inhibition with MG132 sensitized hepatocellular carcinoma cells despite high levels of cFLIP. Although NK and T cell-mediated killing of b-AP15-treated tumor cells was reduced in presence of neutralizing antibodies to TRAIL, killing was also reduced in the presence of neutralizing antibodies to Fas ligand or CMA. Therefore, we cannot exclude that b-AP15 sensitizes tumor cells partly to Fas ligand and perforin-mediated killing. This interpretation would be consistent with the report by Hallett et al. [24] that treatment with proteasome inhibitors can sensitize tumor cells not only to TRAIL-mediated killing, but also to killing via Fas ligand in vitro.
We have previously demonstrated that treatment with b-A15 results in reduced metastases and tumor growth [16] . Similarly, in this study, we observed delayed tumor Several clinical studies have evaluated TRAIL receptor targeting in solid tumors. These studies concluded that TRAIL targeting needs to be combined with chemotherapy to generate objective clinical response rates [28] [29] [30] . Combined therapy with drugs like b-AP15 and adoptive cell therapy may have additional benefits over the use of combining immunosensitizing drugs and agonistic monoclonal antibodies against TRAIL or recombinant TRAIL for several reasons. The half-life of anti-TRAIL receptor antibodies and recombinant TRAIL is approximately 17 days and less than 1 h, respectively [31] . Adoptively transferred T and NK cells can be detected several months after infusion potentially resulting in sustained anti-tumor effects [3, 32] . Our results indicate that following exposure to b-AP15, tumor cells remained sensitive to NK cell killing for 72 h in vitro, thus providing a relatively long therapeutic window for NK cell therapy (data not shown). Infused lymphocytes upon tumor interaction produce pro-inflammatory cytokines that contribute to tumor eradication. Such cytokines may also recruit other inflammatory cells to the tumor microenvironment further heightening the anti-tumor immune response. In addition, tumor cells can develop resistance to TRAIL targeting by monoclonal antibodies. Since NK and T cells use a variety of cytolytic mechanism to induce cell death, drug-induced sensitization combined with adoptive cell infusion may offer a broader anti-tumor effect.
Our findings demonstrate that inhibition of proteasome deubiquitinating activity with b-AP15 renders tumor cells sensitive to killing by NK and T cells. Since combined therapy with NK and T cells increase the chances of targeting tumor cells with variable MHC class I expression, b-AP15 pre-treatment followed by infusion of NK and T cells may represent a valuable therapeutic option for the treatment of a wide variety of cancers.
